Literature DB >> 12527619

Microbiological testing and outcome of patients with severe community-acquired pneumonia.

Jordi Rello1, Maria Bodi, Dolors Mariscal, Marta Navarro, Emili Diaz, Miguel Gallego, Jordi Valles.   

Abstract

STUDY
OBJECTIVES: The study documents the impact of microbiological investigations on therapeutic decisions and outcome in patients with severe community-acquired pneumonia (SCAP).
DESIGN: Retrospective analysis of prospectively collected data.
SETTING: ICUs in two teaching Spanish hospitals. PATIENTS: Two hundred four consecutive patients admitted to intensive care with SCAP.
INTERVENTIONS: None. MEASUREMENTS AND
RESULTS: One hundred six patients required intubation, while 98 other patients did not (81 of these patients were managed with noninvasive mechanical ventilation). The microbiologic diagnosis was established in 57.3% of patients. The most common pathogens were Streptococcus pneumoniae, Legionella pneumophila, and Haemophilus influenzae. Pseudomonas (6.6.% vs 1.0%, p < 0.05) and Legionella (15.1% vs 7.1%, p < 0.05) were more frequently documented in intubated patients. Overall mortality was 23.5% (44.3% in intubated patients), with S pneumoniae (n = 7), Pseudomonas aeruginosa (n = 7), and L pneumophila (n = 5) being the most common lethal pathogens. Bacteriological investigation led to changes in antibiotic prescription in 41.6% of patients, including 11 patients (5%) in whom initial treatment was ineffective against the microbial isolates. The most frequent reason for changes was simplification of therapy in 65 episodes (31.8%).
CONCLUSIONS: We conclude that microbiological testing is fully justified in patients with SCAP, because identifying the causative agent and adjusting treatment both impact on patient outcome. Our findings suggest that intubated patients should be empirically treated for Pseudomonas and Legionella while awaiting bacteriology results.

Entities:  

Mesh:

Year:  2003        PMID: 12527619     DOI: 10.1378/chest.123.1.174

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  31 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Treatment of Legionnaires' disease.

Authors:  Guy W Amsden
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

4.  Linking joint commission inpatient core measures and national patient safety goals with evidence.

Authors:  Andrew L Masica; Kathleen M Richter; Paul Convery; Ziad Haydar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-04

5.  Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy.

Authors:  Christopher R Frei; Sylvie Rehani; Grace C Lee; Natalie K Boyd; Erene Attia; Ashley Pechal; Rachel S Britt; Eric M Mortensen
Journal:  Pharmacotherapy       Date:  2017-02-03       Impact factor: 4.705

6.  Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.

Authors:  I Martin-Loeches; T Lisboa; A Rodriguez; C Putensen; D Annane; J Garnacho-Montero; M I Restrepo; J Rello
Journal:  Intensive Care Med       Date:  2009-12-02       Impact factor: 17.440

Review 7.  The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis.

Authors:  M H Rozenbaum; P Pechlivanoglou; T S van der Werf; J R Lo-Ten-Foe; M J Postma; E Hak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-14       Impact factor: 3.267

Review 8.  Value of RVP in clinical settings: intensive care.

Authors:  Tony Mazzulli
Journal:  J Clin Virol       Date:  2007-11       Impact factor: 3.168

9.  The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit.

Authors:  Chih-Yen Tu; Wu-Huei Hsu; Te-Chun Hsia; Hung-Jen Chen; Kuo-Liang Chiu; Liang-Wen Hang; Chuen-Ming Shih
Journal:  Intensive Care Med       Date:  2006-02-15       Impact factor: 17.440

10.  Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough.

Authors:  Alejandro Rodriguez; Thiago Lisboa; Stijn Blot; Ignacio Martin-Loeches; Jorge Solé-Violan; Diego De Mendoza; Jordi Rello
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.